According to Coluccia serves as “a guarantor of qualityà of the data banks on drugs” to fill the gaps highlighted from the document.
“The problem seems to be a certain ‘weakness’ of clinical information to the doctor – says Coluccia – And this has reasons well understood. All of the software-house – explains – they use the data banks of the medicines ‘designed’ for the distribution.
Therefore, aspects of the product (such as notes and ricettabilità) are well-cared for, unlike the clinical aspects (possible interactions with foods or other drugs)”.
The evaluation shows that the products on the market in the media are good – it lays claim to the president of DS Medical – but need to be improved. In short, the dossier came to some very interesting indications.
And già different software-houses are working to improve. Us, for example – says – we made an international agreement to deploy MD Consult , a well-known system of clinical decision support”.
But the real need is to be able to rely on a guarantor for the qualityà of the data banks. A role – concludes Coluccia that would cover the same Aifa (Italian drug Agency)”.
Celiac disease: symptoms, testing, diagnosis, and treatment
Page published on July 27, 2009